港股異動 | 四環醫藥(0460.HK)漲超8% 獲授予琥珀酸美託洛爾緩釋片中國大陸獨家推廣權
格隆匯5月28日丨四環醫藥(0460.HK)午後直線拉昇,現報3.72港元,漲8.14%,暫成交3億港元,最新市值352億港元。四環醫藥今日午間宣佈,集團附屬海南四環醫藥有限公司與佛山德芮可製藥有限公司簽訂了有關琥珀酸美託洛爾緩釋片23.75mg/47.5mg/95mg/190mg的產品總營銷服務協議。根據該協議,德芮可向集團授予該產品於中國大陸地區的產品獨家市場推廣權。根據中國米內資料庫統計,琥珀酸美託洛爾緩釋片於2018年中國城市公立醫院的銷售額約為人民幣13億元。目前市場上除了阿斯利康的原研產品獨家在售外,尚無仿製藥獲批。此次集團所代理的該產品目前處於優先評審階段。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.